Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy

L. Milazzo, M. Corbellino, A. Foschi, V. Micheli, A. Dodero, A. Mazzocchi, V. Montefusco, G. Zehender, S. Antinori

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.

Original languageEnglish
Pages (from-to)95-98
Number of pages4
JournalTransplant Infectious Disease
Volume14
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Tenofovir
Lamivudine
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Hepatitis B virus
Antiviral Agents
Transplants
Hepatitis B Antibodies
Non-Hodgkin's Lymphoma
Mortality
Therapeutics
entecavir

Keywords

  • Allogeneic hematopoietic stem cell transplant
  • Entecavir
  • HBV reactivation
  • Hepatitis B virus
  • Tenofovir

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation : Successful treatment with combined entecavir plus tenofovir therapy. / Milazzo, L.; Corbellino, M.; Foschi, A.; Micheli, V.; Dodero, A.; Mazzocchi, A.; Montefusco, V.; Zehender, G.; Antinori, S.

In: Transplant Infectious Disease, Vol. 14, No. 1, 02.2012, p. 95-98.

Research output: Contribution to journalArticle

@article{dcdfce48bbbf42eab5c04eb73fd0cf74,
title = "Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy",
abstract = "Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.",
keywords = "Allogeneic hematopoietic stem cell transplant, Entecavir, HBV reactivation, Hepatitis B virus, Tenofovir",
author = "L. Milazzo and M. Corbellino and A. Foschi and V. Micheli and A. Dodero and A. Mazzocchi and V. Montefusco and G. Zehender and S. Antinori",
year = "2012",
month = "2",
doi = "10.1111/j.1399-3062.2011.00659.x",
language = "English",
volume = "14",
pages = "95--98",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation

T2 - Successful treatment with combined entecavir plus tenofovir therapy

AU - Milazzo, L.

AU - Corbellino, M.

AU - Foschi, A.

AU - Micheli, V.

AU - Dodero, A.

AU - Mazzocchi, A.

AU - Montefusco, V.

AU - Zehender, G.

AU - Antinori, S.

PY - 2012/2

Y1 - 2012/2

N2 - Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.

AB - Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.

KW - Allogeneic hematopoietic stem cell transplant

KW - Entecavir

KW - HBV reactivation

KW - Hepatitis B virus

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84857058379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857058379&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3062.2011.00659.x

DO - 10.1111/j.1399-3062.2011.00659.x

M3 - Article

C2 - 21749588

AN - SCOPUS:84857058379

VL - 14

SP - 95

EP - 98

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 1

ER -